Mais la polymyxine n'est pas du tout absorbée dans le sang du système gastro-intestinal et n'a d'effet que dans l'intestin et est utile pour le traitement des infections intestinales amoxicilline prix Internet en y faisant des achats permettant d’économiser jusqu'à soixante-dix pour cent, tout en étant sûr de la qualité des produits pharmaceutiques.

Lf_lw_g_anl_6.1_wskat_frei_01012013rev02_en

Annex 6.1 QS Active Agent Catalogue for Poultry The subsequent table contains a complete list of the active substances in veterinary medicines which are approved in Germany for application to poultry. In consideration of the various domestic regulations regarding the waiting period and duration, the following applies: 1. Legally binding is invariably the waiting period indicated on the formulation to be applied, hence the waiting period upon which the approval has been based. 2. A shorter waiting period than listed in the table may be applied if two conditions are fulfilled: a. The shorter waiting period ensues from an official governmental approval according to legal b. The shorter waiting period shall not fall below the shortest waiting period of the EU, and has to 3. If longer waiting periods apply according to legal regulations in the country of origin, these should be observed. A non-approved veterinary medicine according to legal regulations in the country of origin 4. Adherence to all three requirements must be documented. This list is produced using the medication information system (AMIS) of the German medication authority All waiting periods refer to eatable tissues, waiting periods for eggs were not considered. Waiting periods are pharmaceutical product specific not active agent. It is influenced by dose, pharmaceutical form, application form etc. The waiting periods here indicated refer to formulations approved in Germany for application including waiting period-ranges for the respective animal species. Shorter waiting periods than 48 hours will be indicated with 48 hours (= 2 days). Active substances for which approved veterinary medicines exist in Germany for at least one Guideline Agriculture Poultry Production Annex 6.1 QS Active Agent Catalogue for Poultry a There are no medications with this active agent approved for this species. Therefore, according to § 56a of the Medication Law, this can be rededicated in a minimum waiting time of 28 days for eatable tissue according to § 12a of the Veterinary health regulation. Guideline Agriculture Poultry Production Annex 6.1 QS Active Agent Catalogue for Poultry b The shortest waiting period of this active substance is shorter than 48 hours. Applying this to QS-poultry compliance with the waiting period of 48 hours is mandatory. c Reporting requirements: The use of this substance is linked to a reporting requirement to the office of QS. The notice has to be given at first day in written form to: QS Fachgesellschaft Geflügel GmbH Schedestraße 1-3, D-53113 Bonn Guideline Agriculture Poultry Production Annex 6.1 QS Active Agent Catalogue for Poultry QS Fachgesellschaft Geflügel GmbH Managing Director Dr. Hermann-Josef Nienhoff Schedestraße 1-3 53113 Bonn Tel +49 228 35068-0 Fax +49 228 35068-10 [email protected] www.q-s.de Guideline Agriculture Poultry Production Annex 6.1 QS Active Agent Catalogue for Poultry

Source: http://www.xn--team-qualitt-qcb.net/services/files/downloadcenter/1_anlagen/gefluegelmast/lf_lw_g_anl_6.1_wskat_frei_01012013rev02_en.pdf

Untitled

RTI FACT SHEET #15 Advanced Quality Control And Standardization Technology For Better Special Forest Products Management Recent interest in Special Forest Product (SFP) collections has called for a need to improve the quality, efficacy, and safety of medicinal botanicals and herbal nutrient supplements. High quality and consistent SFP have customarily brought a higher market

ecolomics-international.org

From Global Enclosure to Self Enclosure: Ten Years After – A Critique of the CBD and the “Bonn Guidelines” on Access and Benefit Sharing (ABS) Issue: Since 1994, the Convention on Biological Diversity (CBD) has been promising “benefit sharing” to Indigenous Peoples in return for access to biodiversity (i.e., bioprospecting). During these tenyears, Indigenous People

Copyright © 2010-2014 Medical Science